Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Hepatitis C

  Free Subscription


Articles published in J Gastroenterol

Retrieve available abstracts of 40 articles:
HTML format



Single Articles


    October 2020
  1. MIKI D, Akita T, Kurisu A, Kawaoka T, et al
    PNPLA3 and HLA-DQB1 polymorphisms are associated with hepatocellular carcinoma after hepatitis C virus eradication.
    J Gastroenterol. 2020 Oct 15. pii: 10.1007/s00535-020-01731.
    PubMed     Abstract available


  2. TAHATA Y, Hikita H, Mochida S, Kawada N, et al
    Sofosbuvir plus velpatasvir treatment for hepatitis C virus in patients with decompensated cirrhosis: a Japanese real-world multicenter study.
    J Gastroenterol. 2020 Oct 1. pii: 10.1007/s00535-020-01733.
    PubMed     Abstract available


    August 2020
  3. NAKAGAWA M, Nawa N, Takeichi E, Shimizu T, et al
    Mac-2 binding protein glycosylation isomer as a novel predictive biomarker for patient survival after hepatitis C virus eradication by DAAs.
    J Gastroenterol. 2020 Aug 8. pii: 10.1007/s00535-020-01715.
    PubMed     Abstract available


    February 2020
  4. TAKEHARA T, Chayama K, Kurosaki M, Yatsuhashi H, et al
    JNJ-4178 (adafosbuvir, odalasvir, and simeprevir) in Japanese patients with chronic hepatitis C virus genotype 1 or 2 infection with or without compensated cirrhosis: the Phase IIa OMEGA-3 study.
    J Gastroenterol. 2020 Feb 17. pii: 10.1007/s00535-020-01672.
    PubMed     Abstract available


    September 2019
  5. PUIGVEHI M, Londono MC, Torras X, Lorente S, et al
    Impact of sustained virological response with DAAs on gastroesophageal varices and Baveno criteria in HCV-cirrhotic patients.
    J Gastroenterol. 2019 Sep 6. pii: 10.1007/s00535-019-01619.
    PubMed     Abstract available


    June 2019
  6. MIZUNO K, Toyoda H, Yasuda S, Tada T, et al
    The course of elderly patients with persistent hepatitis C virus infection without hepatocellular carcinoma.
    J Gastroenterol. 2019 Jun 3. pii: 10.1007/s00535-019-01595.
    PubMed     Abstract available


    March 2019
  7. SEZAKI H, Suzuki F, Hosaka T, Fujiyama S, et al
    Initial- and re-treatment effectiveness of glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C virus-genotype 1/2/3 infections.
    J Gastroenterol. 2019 Mar 22. pii: 10.1007/s00535-019-01575.
    PubMed     Abstract available


  8. NAGANUMA A, Chayama K, Notsumata K, Gane E, et al
    Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection.
    J Gastroenterol. 2019 Mar 13. pii: 10.1007/s00535-019-01569.
    PubMed     Abstract available


  9. TAKAGUCHI K, Toyoda H, Tsutsui A, Suzuki Y, et al
    Real-world virological efficacy and safety of daclatasvir/asunaprevir/beclabuvir in patients with chronic hepatitis C virus genotype 1 infection in Japan.
    J Gastroenterol. 2019 Mar 8. pii: 10.1007/s00535-019-01568.
    PubMed     Abstract available


    February 2019
  10. UEDA Y, Kobayashi T, Ikegami T, Miuma S, et al
    Efficacy and safety of glecaprevir and pibrentasvir treatment for 8 or 12 weeks in patients with recurrent hepatitis C after liver transplantation: a Japanese multicenter experience.
    J Gastroenterol. 2019 Feb 26. pii: 10.1007/s00535-019-01561.
    PubMed     Abstract available


  11. SUDA G, Hasebe C, Abe M, Kurosaki M, et al
    Safety and efficacy of glecaprevir and pibrentasvir in Japanese hemodialysis patients with genotype 2 hepatitis C virus infection.
    J Gastroenterol. 2019 Feb 18. pii: 10.1007/s00535-019-01556.
    PubMed     Abstract available


    January 2019
  12. DOI A, Hikita H, Kai Y, Tahata Y, et al
    Combinations of two drugs among NS3/4A inhibitors, NS5B inhibitors and non-selective antiviral agents are effective for hepatitis C virus with NS5A-P32 deletion in humanized-liver mice.
    J Gastroenterol. 2019 Jan 25. pii: 10.1007/s00535-018-01541.
    PubMed     Abstract available


  13. KIMURA K
    Long-awaited treatment for hepatitis C virus decompensated cirrhosis.
    J Gastroenterol. 2019 Jan 1. pii: 10.1007/s00535-018-01538.
    PubMed    


    November 2018
  14. RAKSAYOT M, Chuaypen N, Khlaiphuengsin A, Pinjaroen N, et al
    Independent and additive effects of PNPLA3 and TM6SF2 polymorphisms on the development of non-B, non-C hepatocellular carcinoma.
    J Gastroenterol. 2018 Nov 30. pii: 10.1007/s00535-018-01533.
    PubMed     Abstract available


    October 2018
  15. IIO E, Matsuura K, Shimada N, Atsukawa M, et al
    TLL1 variant associated with development of hepatocellular carcinoma after eradication of hepatitis C virus by interferon-free therapy.
    J Gastroenterol. 2018 Oct 31. pii: 10.1007/s00535-018-1526.
    PubMed     Abstract available


  16. OSAWA M, Imamura M, Teraoka Y, Uchida T, et al
    Real-world efficacy of glecaprevir plus pibrentasvir for chronic hepatitis C patient with previous direct-acting antiviral therapy failures.
    J Gastroenterol. 2018 Oct 17. pii: 10.1007/s00535-018-1520.
    PubMed     Abstract available


    September 2018
  17. TAKEHARA T, Sakamoto N, Nishiguchi S, Ikeda F, et al
    Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial.
    J Gastroenterol. 2018 Sep 10. pii: 10.1007/s00535-018-1503.
    PubMed     Abstract available


    July 2018
  18. SUDA G, Kurosaki M, Itakura J, Izumi N, et al
    Safety and efficacy of elbasvir and grazoprevir in Japanese hemodialysis patients with genotype 1b hepatitis C virus infection.
    J Gastroenterol. 2018 Jul 17. pii: 10.1007/s00535-018-1495.
    PubMed     Abstract available


  19. MAEKAWA S, Enomoto N
    The "real-world" efficacy and safety of DAAs for the treatment of HCV patients throughout Japan.
    J Gastroenterol. 2018 Jul 6. pii: 10.1007/s00535-018-1493.
    PubMed    


    May 2018
  20. TOYODA H, Atsukawa M, Takaguchi K, Senoh T, et al
    Real-world virological efficacy and safety of elbasvir and grazoprevir in patients with chronic hepatitis C virus genotype 1 infection in Japan.
    J Gastroenterol. 2018 May 8. pii: 10.1007/s00535-018-1473.
    PubMed     Abstract available


    April 2018
  21. TSUJI K, Kurosaki M, Itakura J, Mori N, et al
    Real-world efficacy and safety of ledipasvir and sofosbuvir in patients with hepatitis C virus genotype 1 infection: a nationwide multicenter study by the Japanese Red Cross Liver Study Group.
    J Gastroenterol. 2018 Apr 6. pii: 10.1007/s00535-018-1455.
    PubMed     Abstract available


    March 2018
  22. AKUTA N, Toyota J, Karino Y, Ikeda F, et al
    Potent viral suppression and improvements in alpha-fetoprotein and measures of fibrosis in Japanese patients receiving a daclatasvir/asunaprevir/beclabuvir fixed-dose combination for the treatment of HCV genotype-1 infection.
    J Gastroenterol. 2018 Mar 2. pii: 10.1007/s00535-018-1445.
    PubMed     Abstract available


    January 2018
  23. ZEUZEM S, Serfaty L, Vierling J, Cheng W, et al
    The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection.
    J Gastroenterol. 2018 Jan 17. pii: 10.1007/s00535-018-1429.
    PubMed     Abstract available


  24. SUDA G, Ogawa K, Morikawa K, Sakamoto N, et al
    Treatment of hepatitis C in special populations.
    J Gastroenterol. 2018 Jan 3. pii: 10.1007/s00535-017-1427.
    PubMed     Abstract available


    November 2017
  25. KUMADA H, Watanabe T, Suzuki F, Ikeda K, et al
    Correction to: Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection.
    J Gastroenterol. 2017 Nov 13. doi: 10.1007/s00535-017-1409.
    PubMed     Abstract available


  26. MAEKAWA S, Sato M, Kuratomi N, Inoue T, et al
    Association between alanine aminotransferase elevation and UGT1A1*6 polymorphisms in daclatasvir and asunaprevir combination therapy for chronic hepatitis C.
    J Gastroenterol. 2017 Nov 1. doi: 10.1007/s00535-017-1405.
    PubMed     Abstract available


    October 2017
  27. KUMADA H, Watanabe T, Suzuki F, Ikeda K, et al
    Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection.
    J Gastroenterol. 2017 Oct 20. doi: 10.1007/s00535-017-1396.
    PubMed     Abstract available


  28. WANG W, Pan Q, Fuhler GM, Smits R, et al
    Erratum to: Action and function of Wnt/beta-catenin signaling in the progression from chronic hepatitis C to hepatocellular carcinoma.
    J Gastroenterol. 2017 Oct 11. doi: 10.1007/s00535-017-1392.
    PubMed     Abstract available


    September 2017
  29. CHAYAMA K, Suzuki F, Karino Y, Kawakami Y, et al
    Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis.
    J Gastroenterol. 2017 Sep 25. doi: 10.1007/s00535-017-1391.
    PubMed     Abstract available


    August 2017
  30. KAWAKAMI Y, Ochi H, Hayes CN, Imamura M, et al
    Efficacy and safety of ledipasvir/sofosbuvir with ribavirin in chronic hepatitis C patients who failed daclatasvir/asunaprevir therapy: pilot study.
    J Gastroenterol. 2017 Aug 16. doi: 10.1007/s00535-017-1380.
    PubMed     Abstract available


    May 2017
  31. MIZUOCHI T, Takano T, Yanagi T, Ushijima K, et al
    Epidemiologic features of 348 children with hepatitis C virus infection over a 30-year period: a nationwide survey in Japan.
    J Gastroenterol. 2017 May 31. doi: 10.1007/s00535-017-1351.
    PubMed     Abstract available


  32. SUDA G, Furusyo N, Toyoda H, Kawakami Y, et al
    Daclatasvir and asunaprevir in hemodialysis patients with hepatitis C virus infection: a nationwide retrospective study in Japan.
    J Gastroenterol. 2017 May 30. doi: 10.1007/s00535-017-1353.
    PubMed     Abstract available


    January 2017
  33. UEDA Y, Ikegami T, Akamatsu N, Soyama A, et al
    Treatment with sofosbuvir and ledipasvir without ribavirin for 12 weeks is highly effective for recurrent hepatitis C virus genotype 1b infection after living donor liver transplantation: a Japanese multicenter experience.
    J Gastroenterol. 2017 Jan 30. doi: 10.1007/s00535-017-1310.
    PubMed     Abstract available


    December 2016
  34. WANG W, Pan Q, Fuhler GM, Smits R, et al
    Action and function of Wnt/beta-catenin signaling in the progression from chronic hepatitis C to hepatocellular carcinoma.
    J Gastroenterol. 2016 Dec 29. doi: 10.1007/s00535-016-1299.
    PubMed     Abstract available


  35. OGAWA E, Furusyo N, Nomura H, Dohmen K, et al
    NS5A resistance-associated variants undermine the effectiveness of ledipasvir and sofosbuvir for cirrhotic patients infected with HCV genotype 1b.
    J Gastroenterol. 2016.
    PubMed     Abstract available


    November 2016
  36. KUMADA H, Suzuki Y, Karino Y, Chayama K, et al
    The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II/III study.
    J Gastroenterol. 2016.
    PubMed     Abstract available


  37. MORIO K, Imamura M, Kawakami Y, Nakahara T, et al
    ITPA polymorphism effects on decrease of hemoglobin during sofosbuvir and ribavirin combination treatment for chronic hepatitis C.
    J Gastroenterol. 2016.
    PubMed     Abstract available


    October 2016
  38. TAKEDA H, Takai A, Inuzuka T, Marusawa H, et al
    Genetic basis of hepatitis virus-associated hepatocellular carcinoma: linkage between infection, inflammation, and tumorigenesis.
    J Gastroenterol. 2016.
    PubMed     Abstract available


    September 2016
  39. MORIO R, Imamura M, Kawakami Y, Morio K, et al
    Safety and efficacy of dual therapy with daclatasvir and asunaprevir for older patients with chronic hepatitis C.
    J Gastroenterol. 2016.
    PubMed     Abstract available


    November 2015
  40. KAWAI-KITAHATA F, Asahina Y, Tanaka S, Kakinuma S, et al
    Comprehensive analyses of mutations and hepatitis B virus integration in hepatocellular carcinoma with clinicopathological features.
    J Gastroenterol. 2015.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis C is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: